SOURCE: Apogee Technology, Inc.

May 08, 2008 08:45 ET

Apogee Initiates Study With the Institute for Aging Research to Support Its Health Monitoring Product Development

NORWOOD, MA--(Marketwire - May 8, 2008) - Apogee Technology, Inc. (OTCBB: ATCS) today announced an agreement with Hebrew SeniorLife's Institute for Aging Research (IFAR) in Boston, Massachusetts, to conduct studies designed to evaluate Apogee's IntellaPAL™ health monitoring system and to better assess fall-related health conditions in older adults. IFAR is an internationally recognized leader in aging research and a teaching affiliate of Beth Israel Deaconess Medical Center and Harvard Medical School.

David Meyers, Apogee's Vice President, Censor Division, said, "Our study with IFAR demonstrates the ongoing evolution of the IntellaPAL monitoring system from concept to commercial product. The purpose of the study is to evaluate the performance of IntellaPAL in both clinical and home environments. In addition, the data collected during the study will be used to support the further development of IntellaPAL and IFAR's ongoing research in syncope and falls in older adults. Approximately 25 subjects are expected to be enlisted in the study, which is planned to be completed by mid-summer. We plan to conduct follow-up studies, as appropriate, to finalize the design of our monitoring system."

Lewis A. Lipsitz, M.D., Irving and Edyth S. Usen and Family Chair in Medical Research, Institute for Aging Research, Hebrew SeniorLife, and Professor of Medicine, Harvard Medical School, said, "This exciting collaboration between IFAR's gerontological investigators and Apogee's talented engineers will help set the stage for future research in our housing facilities, where we can learn about the process of aging non-invasively with state-of-the-art monitoring technology as people go about their daily lives."

Apogee is developing IntellaPAL to improve the security, independence, and quality of life for older adults and their families. The IntellaPAL system is designed to provide significant benefits over existing personal emergency response systems, or PERS, that only provide a panic button to contact emergency assistance. The IntellaPAL system will add sensors, intelligent software and digital wireless technology to automatically notify first responders and family members when emergency conditions occur, even when the user is unconscious or otherwise unable to initiate a call for help. IntellaPAL will also include a secure online information service that presents health status and capabilities to detect long-term changes in health. With this information, caregivers can take proactive measures to resolve health conditions before they become serious and require emergency care.

About the Institute for Aging Research

Scientists at the Institute for Aging Research conduct rigorous medical and social studies, leading the way in developing strategies for maximizing individuals' strength, vigor and physical well-being, as well as their cognitive and functional independence, in late life. Hebrew SeniorLife is a 100+-year-old organization committed to maximizing quality of life of seniors through an integrated network of housing, health care, research and teaching programs, serving more than 5,000 seniors annually in the Greater Boston area.

About Apogee Technology, Inc.

Apogee Technology, Inc. is developing IntellaPAL™, proprietary sensor-based health monitoring systems for the care of older adults and others that it intends to produce and market to individuals and health organizations. Apogee is also developing PyraDerm™, a proprietary intradermal delivery system for vaccines and pharmaceutical agents, for the treatment and prevention of local and systemic conditions. PyraDerm incorporates structured solid-state formulations designed to penetrate the outer layer of the skin and then release the agent in a controlled manner. For more information please visit our web site at:

PyraDerm™, Sensilica® and IntellaPAL™ are trademarks of Apogee Technology, Inc. All other product names noted herein may be trademarks of their respective holders.

Certain statements made herein that use the words "anticipate," "may," "hope," "estimate," "project," "will," "intend," "plan," "expect," "believe" and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve those oriented to the Company's continued trading status, capital raising transactions and its interaction with future quotation or listing services in addition to those related to the design, development and production efforts of our PyraDerm™, Sensilica® and IntellaPAL™ technologies, known and unknown risks and uncertainties, which could cause the actual results, performance or achievements of the Company to be materially different from those that may be expressed or implied. Please refer to the company's risk factors as set forth in the Company's filings with the Securities and Exchange Commission, including its report on Form 10-KSB for the year ended December 31, 2007.

Contact Information

  • Apogee Investor Contact:
    Paul J. Murphy
    Chief Financial Officer and Vice President of Finance
    Telephone: (781) 551-9450